Prosecution Insights
Last updated: April 19, 2026

Eli Lilly And Company

50 pending office actions

Portfolio Summary

50
Total Pending OAs
13
Final Rejections
37
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
19104909 INFUSION SITE FAILURE DETECTION SHELDEN, BION A 3685 Non-Final OA Feb 19, 2025
18713758 SYSTEMS AND METHODS FOR IDENTIFYING SUBJECTS FOR CLINICAL TRIALS HEIN, DEVIN C 3686 Non-Final OA May 28, 2024
18598084 METHODS AND APPARATUSES FOR DETECTING ANOMALIES WHEN FILLING A CONTAINER WITH FLUID KOPPOLU, VAISALI RAO 2664 Non-Final OA Mar 07, 2024
18686475 SYSTEMS AND METHODS FOR SENSING DEFECATION EVENTS OKONAK, ELIZABETH LOUISE 3792 Non-Final OA Feb 26, 2024
18567814 2019 NOVEL CORONAVIRUS ANTIBODY-CONTAINING PHARMACEUTICAL FORMULATIONS WANG, RUIXUE 1672 Non-Final OA Dec 07, 2023
18523645 THERAPEUTIC USES OF DULAGLUTIDE BEANE, RANDALL L 1654 Final Rejection Nov 29, 2023
18506193 SYNTHETIC NUCLEIC ACIDS INCLUDING ASTROCYTE-DIRECTED PROMOTER CONSTRUCTS AND METHODS OF USING THE SAME BURKHART, MICHAEL D 1638 Non-Final OA Nov 10, 2023
18288314 SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS NOLAN, JASON MICHAEL 1623 Non-Final OA Oct 25, 2023
18552897 TABLET DISPENSER RANDALL, JR., KELVIN L 3651 Final Rejection Sep 28, 2023
18549693 USE OF MEVIDALEN AND OTHER D1 POSITIVE ALLOSTERIC MODULATORS FOR SLOWING OF PARKINSON'S DISEASE PROGRESSION ELENISTE, PIERRE PAUL 1622 Non-Final OA Sep 08, 2023
18549546 USE OF MEVIDALEN AND OTHER D1 POSITIVE ALLOSTERIC MODULATORS IN THE TREATMENT OF HALLUCINATIONS AND DEMENTIA-RELATED PSYCHOSIS PECKHAM, RICHARD GRANT 1627 Non-Final OA Sep 07, 2023
18546477 TIRZEPATIDE THERAPEUTIC METHODS BROWN, DALIYAH MONYHE 1654 Non-Final OA Aug 15, 2023
18262874 METHODS AND APPARATUS FOR INCREMENTAL LEARNING USING STORED FEATURES BROUGHTON, KATHLEEN M 2661 Final Rejection Jul 25, 2023
18262010 STATUS SENSING SYSTEMS FOR CONNECTED INJECTION DEVICE DESANTO, MATTHEW F 3700 Non-Final OA Jul 18, 2023
18260125 ANTI-N3pGlu AMYLOID BETA ANTIBODIES AND USES THEREOF HOPKINS, SAMANTHA LAKE 1641 Non-Final OA Jun 30, 2023
18259500 HALF-LIFE EXTENDING MOIETIES AND METHODS OF USING THE SAME KATAKAM, SUDHAKAR 1658 Non-Final OA Jun 27, 2023
18323674 LASOFOXIFENE COMBINATION TREATMENT OF ER+ BREAST CANCER THAT HAS PROGRESSED ON A CDK4/6 INHIBITOR NOTTINGHAM, KYLE GREGORY 1621 Non-Final OA May 25, 2023
18317282 OSCILLATING FLUIDIZED BED OLIGONUCLEOTIDE SYNTHESIZER LAU, JONATHAN S 1693 Non-Final OA May 15, 2023
18143902 VARIANT ADENO-ASSOCIATED VIRUS (AAV) CAPSID POLYPEPTIDES AND GENE THERAPEUTICS THEREOF FOR TREATMENT OF HEARING LOSS SHIBUYA, MARK LANCE 1631 Non-Final OA May 05, 2023
18312653 HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES ALDARONDO, DASIA ALI 1647 Non-Final OA May 05, 2023
18247084 METHODS FOR REDUCING HOST CELL PROTEIN CONTENT IN PROTEIN PURIFICATION PROCESSES CHHAY, BONIRATH 1645 Non-Final OA Mar 29, 2023
18245425 ORAL DRUG DELIVERY DEVICE WITH EXPANDING BAND TRUONG, QUANGLONG N 1615 Non-Final OA Mar 15, 2023
18044618 DEVICES AND PROCESSES FOR DELIVERY OF THERAPEUTIC FLUIDS DARB, HAMZA A. 3783 Non-Final OA Mar 09, 2023
18044504 Therapeutic Antibody Formulations NOAKES, SUZANNE MARIE 1656 Non-Final OA Mar 08, 2023
18176844 THERAPEUTIC ANTIBODY FORMULATION KIM, YUNSOO 1641 Non-Final OA Mar 01, 2023
18041898 METHODS AND APPARATUS FOR DISPLAYING GLUCOSE DATA HALPRIN, MOLLY SARA 3791 Final Rejection Feb 16, 2023
17787015 ENDOTOXIN DETECTION FRITCHMAN, REBECCA M 1758 Non-Final OA Feb 06, 2023
18006593 PHYSIOLOGICAL DATA MONITORING SYSTEM SWEARINGEN, JEFFREY R 2445 Final Rejection Jan 24, 2023
18005245 LOW DOSE REGIMEN AND FORMULATION OF A 5-METHYL-1,2,4-OXADIAZOL-3-YL COMPOUND MOU, LIYUAN 1628 Final Rejection Jan 12, 2023
18149982 METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE SABILA, MERCY HELLEN 1654 Non-Final OA Jan 04, 2023
18011965 PREVENTION OF AXONAL DAMAGE USING ANTIBODY BINDING TO AMYLOID BETA 1-42 WANG, CHANG YU 1675 Non-Final OA Dec 21, 2022
17920118 PAN-ELR+ CXC CHEMOKINE ANTIBODIES FOR THE TREATMENT OF RESPIRATORY DISEASE SAOUD, CHRISTINE J 1645 Non-Final OA Oct 20, 2022
17906580 FARNESOID X RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASE BURKETT, DANIEL JOHN 1624 Final Rejection Sep 16, 2022
17911746 METHOD FOR TREATING IDH1 INHIBITOR-RESISTANT SUBJECTS VALLE, ERNESTO 1623 Non-Final OA Sep 15, 2022
17905520 MULTISPECIFIC BINDING PROTEINS AND METHODS OF DEVELOPING THE SAME ROONEY, NORA MAUREEN 1641 Non-Final OA Sep 02, 2022
17883072 Anti-CGRP Antibody Formulation WANG, CHANG YU 1675 Final Rejection Aug 08, 2022
17794128 GIP/GLP1 CO-AGONIST COMPOUNDS HELLMAN, KRISTINA M 1654 Non-Final OA Jul 20, 2022
17779463 MEDICATION DELIVERY DEVICE WITH SENSING SYSTEM WITTLIFF, KATERINA ANNA 3783 Non-Final OA May 24, 2022
17743864 Treatment of Genital Psoriasis JIANG, DONG 1674 Non-Final OA May 13, 2022
17689286 Methods of treating cancer using a combination of SERD Dosing Regimens ADLAM, CHANTAL PETA-GAYE 1622 Non-Final OA Mar 08, 2022
17633631 METHODS OF MAKING INCRETIN ANALOGS REYNOLDS, FRED H 1658 Final Rejection Feb 08, 2022
17554713 Anti-CGRP Antibody Formulation BORGEEST, CHRISTINA M 1675 Non-Final OA Dec 17, 2021
17619289 SYSTEMS AND METHODS FOR DETECTING MISSED BOLUS DOSES PLAYER, ROBERT AUSTIN 1686 Final Rejection Dec 15, 2021
17535059 COMPOUNDS AND METHODS TARGETING HUMAN TAU BALLARD, KIMBERLY 1675 Non-Final OA Nov 24, 2021
17439066 INTEGRATED INSERTER/APPLICATOR FOR A DRUG DELIVERY SYSTEM PROVIDING MULTIPLE WEAR CONFIGURATIONS THOMAN, EVELYN ANNE 3783 Non-Final OA Sep 14, 2021
17462872 ENDOCRINE THERAPY AND ABEMACICLIB COMBINATION FOR THE ADJUVANT TREATMENT OF NODE-POSITIVE, EARLY STAGE, HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE BREAST CANCER SEITZ, ANTHONY JOSEPH 1629 Final Rejection Aug 31, 2021
17433795 MEDICATION DELIVERY DEVICE WITH SENSING SYSTEM DARB, HAMZA A. 3783 Non-Final OA Aug 25, 2021
17354195 Antibodies that bind TGF-Alpha and Epiregulin for use in the treatment of pain ALLEN, MARIANNE P 1647 Final Rejection Jun 22, 2021
17211163 COMBINATION THERAPY BALLARD, KIMBERLY 1675 Non-Final OA Mar 24, 2021
15733970 COMPOSITIONS AND METHODS OF USE OF IL-10 AGENTS IN CONJUNCTION WITH CHIMERIC ANTIGEN RECEPTOR CELL THERAPY SKELDING, ZACHARY S 1644 Final Rejection Dec 01, 2020

Managing Eli Lilly And Company's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month